Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response

Thumbnail
View/Open
Issue date
2013
Author
Sánchez Rovira, Pedro
Seguí, M. A.
Llombart, A.
Aranda, Enrique
Antón, Antonio
Sánchez, A.
Lomas, M.
Jaén, A.
Fernández, M.
Porras, I.
Dalmau, E.
Morales Murillo, Serafín
Haba-Rodríguez, J. de la
Suggested citation
Sánchez Rovira, Pedro; Seguí, M. A.; Llombart, A.; Aranda, Enrique; Antón, Antonio; Sánchez, A.; ... Haba-Rodríguez, J. de la. (2013) . Bevacizumab plus preoperative chemotherapy in operable HER2 negative breast cancer: biomarkers and pathologic response. Clinical & Translational Oncology, 2013, vol. 15, núm. 10, p. 810-817. https://doi.org/10.1007/s12094-013-1006-4.
Impact

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
Purpose: The primary aim of this trial was to assess the rate of pathologic complete responses (pCR) of doxorubicin/cyclophosphamide (AC) followed by bevacizumab/docetaxel (BT), as neoadjuvant therapy for breast cancer (BC). Furthermore, the association between biomarkers and the pCR was explored. Methods: Patients with HER-negative operable stage II–III BC ≥2 cm were enrolled. Four cycles of AC (A 60 mg/m2 and C 600 mg/m2, every 3 weeks) followed by 4 cycles of BT (B 15 mg/kg and T 75 mg/m2, every 3 weeks), were planned. A core-biopsy was performed for biological markers assessment. Results: Seventy-two women were included. Forty-three (63 %) patients were hormone receptor-positive. Sixty-four (89 %) completed the planned treatment, and 66 evaluable patients underwent surgery (92 %): a pCR was achieved in 16 of them (24, 95 % CI 15–36 %). pCR was significantly higher in tumors hormone receptor-negative, and in those with Angiotensin II type 1 receptor (AGTR1) protein overexpression. The overall clinical response rate was 86 % (95 % CI 76–93 %), including 42 complete responses. No unexpected toxicities or treatment-related deaths were observed. Conclusion: This regimen showed a remarkable clinical and pathological activity: the suggested relation between pCR and AGTR1 overexpression should be confirmed in larger trials.
URI
http://hdl.handle.net/10459.1/70819
DOI
https://doi.org/10.1007/s12094-013-1006-4
Is part of
Clinical & Translational Oncology, 2013, vol. 15, núm. 10, p. 810-817
Collections

The following license files are associated with this item:

cc-by (c) Sánchez-Rovira et al., 2013
Except where otherwise noted, this item's license is described as cc-by (c) Sánchez-Rovira et al., 2013